About Us

About EVolution Therapeutics

Our Vision to Transform

At EVolution Therapeutics, we’re pioneering a transformative approach to inflammatory disease treatment using advanced nanoparticle-based therapeutics. Our research focuses on the design and delivery of immunologically informed nanoparticles, enabling targeted delivery of bioactive payloads and modulating inflammation at its source. Through open innovation and collaboration, we aim to redefine disease management by developing active treatment solutions that address significant unmet medical needs.

Our Timeline

EVolution Therapeutics has swiftly advanced since its inception. The journey began in June 2022 with entry into the BBSRC ICURE ‘Exploit’ programme. Since then, we have continually grown with various grant funding and awards. 

Jun 22

Entered the BBSRC ICURE ‘Exploit’ programme

Dec 22

EVolution Therapeutics incorporated

Mar 23

Secured £284,084 grant funding from Innovate UK’s ICURe Follow-on Fund

Apr 23

Foundational Patent Submitted

Jul 23

Aston University: Convertible Loan Note investment of £50,000

Sep 23

Secured £237,843 grant funding from Innovate UK’s Engineering Biology Collaborative Research and Development grant

Oct 23

Entered Innovate UK’s ICURe Traction programme

Nov 23

Entered SPARK The Midlands accelerator programme

Dec 23

Professor Devitt and Dr Milic awarded £585,000 from the BBSRC Super Follow-on-Fund

Feb 24

New Research Scientist Appointed

May 24

Aston University: Convertible Loan Note investment of £90,000

Jan 24

First Batch of LNPs Produced

Sep 24

Safety & Efficacy Data In-Vivo

Oct 25

Second Patent Submitted

Our Team

Meet our Experts

EVolution Therapeutics is a preclinical-stage biotechnology company spun out of Aston University. Our nanoparticle-based therapeutics represent a next generation approach for the treatment of intractable inflammatory diseases, designed to precisely modulate the innate immune response at sites of pathology. We have assembled a multidisciplinary team with deep expertise in immunology, nanomedicine and translational science, united by a shared focus on advancing innovative therapies from preclinical development towards clinical impact.

Dr. Sri Bellary

Clinical Consultant

Sri Bellary is a Senior NHS diabetes consultant and nationally recognised expert in complex diabetes complications. He has led innovative models of diabetes care and is Deputy Editor-in-Chief of Therapeutic Advances in Endocrinology & Metabolism.

Dr. Matt Vassey

Chief Operating Officer

Matt possesses over a decade of expertise as a business development and technology commercialisation specialist, with a background in fundraising, partnerships, and development of innovative technologies.

Dr. James Gavin

Co-Founder & CEO

With expertise in extracellular vesicles and nano-based therapeutics, Dr Gavin maintains a commercial and growth focus to drive the development of transformative treatments for inflammatory diseases.

Prof. Andrew Devitt

Co-Founder & CTO

With over 30 years of experience in the field of inflammatory cell biology, Andrew Devitt is a distinguished professor and Executive Dean of the School of Medicine, Pharmacy & Biosciences

Dr. Ivana Milic

Co-Founder & CSO

A highly experienced analytical chemist and lecturer in Biosciences at Aston University. Dr Milic possesses world-leading expertise in mass spectrometry for analyses of proteins and highly challenging lipid classes.

Liz Dainty

Chief Financial Officer

Elizabeth qualified as a chartered accountant at KPMG and has over 25 years of experience in both the commercial and charity sectors, holding pivotal fiscal and project management roles with numerous biotech start-ups.